Altering the outer shell of rice bran using enzymes from Hyphomycetes mycelia mushroom extract produces Arabinoxylan compound. The product called MGN-3 (or BioBran® in Japan) is a complex containing arabinoxylan as a major component.
Arabinoxylan has been found to improve immune reactions in diabetes and cancer patients. MGN-3 may also be of potential value in treating AIDS patients or those patients undergoing chemotherapy. However, there is currently a lack of strong human scientific evidence to support the use of arabinoxylan for any indication.
Although presented by manufacturers as a generally safe substance without side effects at recommended doses, the United States Food and Drug Administration (FDA) ordered a permanent court order in 2004 against the marketing of MGN-3, charging that it has been promoted as a drug treatment for cancer, diabetes and HIV.
Arabinoxylane, Arctostaphylos uva-ursi, AX, BioBran®, cinnaman AX, Cinnamomum cassia, Ganoderma lucidum, Hyphomycetes mycelia, kawaratake mushroom, MGN-3, rice bran, shiitake mushroom, suehirotake mushroom.
These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider.
Cancer (various types)
Arabinoxylan has been studied in the treatment of cancer. Additional study is needed in this area.
Diabetes (type 2)
There is currently a lack of scientific evidence investigating the role of arabinoxylan in diabetics. More study is needed before a firm recommendation can be made.